TABLE 2.
Number of treatment‐emergent adverse events (n = 19) (definitely related, probably related, or possibly related to lorcaserin) grouped by System Organ Class and preferred term, for both groups of participants
| Event (System Organ Class/preferred term) | Alcohol use disorder (n = 10) | Methamphetamine use disorder (n = 8) |
|---|---|---|
| Number of participants with ≥1 medication‐related adverse event | 7 | 5 |
| Gastrointestinal disorders | ||
| Diarrhea | 0 | 1 |
| Dry mouth | 2 | 1 |
| Lip dry | 1 | 0 |
| Nausea | 0 | 1 |
| General disorders and administration site conditions | ||
| Lethargy | 3 | 0 |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 3 | 1 |
| Nervous system disorders | ||
| Dizziness | 2 | 0 |
| Headache | 2 | 2 |